18 million people at Africa’s westernmost point; Institut Pasteur de Dakar among the world’s only yellow fever vaccine manufacturers, Niakhar’s 60-year HDSS, the CFA franc’s Euro peg eliminating currency risk, and the gateway to Francophone West Africa’s research corridor.
Sénégal is a presidential republic of approximately 18 million people occupying 196,722 km² at the westernmost point of mainland Africa; located on the Cap-Vert peninsula where the Atlantic Ocean meets the Sahel; bordered by Mauritania to the north, Mali to the east, Guinea and Guinea-Bissau to the south, and entirely enclosing The Gambia’s land borders in the west. Dakar (~3.5–4 million metro), the capital and economic hub situated on Cap-Vert’s Atlantic coast, is one of Africa’s most internationally connected cities: as the regional headquarters for the West African Economic and Monetary Union (UEMOA), ECOWAS’s economic coordination body, and dozens of UN agencies and international organisations, Dakar functions as the diplomatic and commercial capital of Francophone West Africa and; crucially for clinical research; as the region’s most internationally accessible research hub through Blaise Diagne International Airport’s direct daily Air France connections to Paris Charles de Gaulle (approximately 6 hours), with additional connections to Brussels, Casablanca, Lisbon, and New York. Sénégal has been one of Africa’s most stable democracies since independence in 1960; it has never experienced a military coup, and peaceful transfers of power between political parties have occurred multiple times; providing the governmental continuity and institutional stability that underpin long-term research programme investments; the 2024 election of President Bassirou Diomaye Faye marked Senegal’s most recent peaceful democratic transfer of power. Sénégal’s most globally distinctive research institution is the Institut Pasteur de Dakar (IPD); established in 1896, making it one of the oldest scientific research institutions in sub-Saharan Africa and a member of the International Pasteur Network; whose WHO-prequalified yellow fever vaccine manufacturing capability makes IPD Africa’s only yellow fever vaccine producer and one of approximately six institutions worldwide with WHO prequalification to manufacture the 17D yellow fever vaccine; this pharmaceutical manufacturing capability is IPD’s most globally irreplaceable attribute and the foundation of Sénégal’s unique position in flaviviral disease clinical development.
Clinical trials in Sénégal are regulated by the Direction de la Pharmacie, des Laboratoires et du Médicament (DPLM); Sénégal’s pharmaceutical regulatory authority under the Ministry of Health and Social Action; under French-aligned pharmaceutical law and GCP regulations consistent with ICH GCP E6(R2) and WHO GCP standards; research ethics oversight is provided by the Comité National d’Éthique pour la Recherche en Santé (CNERS); Sénégal’s national health research ethics committee; alongside institutional ethics committees at UCAD, IPD, and affiliated hospitals; all regulatory submissions, research documentation, and clinical trial management are conducted in French, which is both the official language of Sénégal and the operational language of the entire Francophone West African research corridor. The West African CFA franc (XOF); pegged to the Euro at 1 EUR = 655.957 XOF since the Euro’s introduction in 1999 (an irrevocable fixed rate guaranteed by France’s Treasury under EU treaty obligations); is Sénégal’s most commercially distinctive operational feature: EUR-denominated European pharmaceutical sponsors conducting research in Sénégal face zero currency risk; operating costs budgeted in EUR translate directly to XOF at the fixed rate with no hedging required; a financial planning certainty completely unavailable in any other sub-Saharan African research market in the GCT series, all of which operate with floating currencies carrying meaningful exchange rate volatility.
Sénégal’s 18 million people are among West Africa’s most culturally and linguistically diverse, spanning the Atlantic coast’s Lebou fishing communities, the central Wolof-speaking groundnut basin, the northern Sahel’s Pulaar/Fula semi-nomadic pastoralists, the Serer farming communities of the Fatick and Kaolack regions (who form the primary population of the Niakhar HDSS research catchment), and the Jola/Diola communities of the Casamance region south of The Gambia. The Wolof (~43%) and Wolof language function as Sénégal’s de facto national lingua franca; spoken by approximately 90% of the population as a first or second language regardless of ethnic background; creating a cultural cohesion that simplifies community engagement, informed consent, and health literacy communication for clinical research programmes in ways that Sénégal’s linguistically fragmented neighbours (Guinea, Mali, Burkina Faso) cannot match; French remains the language of all regulatory and professional research communication, however, and community-level research engagement requires Wolof, Pulaar, or Serer language materials for rural sites. Sénégal’s predominant Sufi Muslim religious culture; with approximately 95% of the population belonging to the Mouride, Tijaniyya, or Qadiriyya brotherhoods whose religious leadership (marabouts) carry significant community authority; creates a specific community engagement dynamic for clinical research: marabout endorsement of research participation has historically accelerated community recruitment in rural and peri-urban Senegalese research sites, while marabout concerns about specific research designs (blood draws; genetic sampling) can require customised community engagement approaches that experienced Senegalese research teams at IPD and UCAD know how to navigate. Pharmacogenomically, Sénégal’s populations represent a distinct West African genetic profile different from Nigeria’s Yoruba-dominated HapMap reference populations: the Wolof, Fula/Pulaar, and Serer populations carry West African Sahelian genetic ancestry profiles whose CYP2D6 and CYP2B6 pharmacogenomic variant frequencies differ meaningfully from the better-characterised Nigerian Yoruba and Igbo pharmacogenomics, creating a Sahelian West African pharmacogenomic research population that fills a gap in the global pharmacogenomics reference database not addressed by Nigeria’s HapMap Yoruba or Ghana’s Akan populations.
Sénégal’s disease burden is shaped by its Sahelian ecology and relatively low income, but is notably distinct from the Southern and East African arc countries: Malaria (~3–4 million cases annually) is seasonal (concentrated July–November in the rainy season) and predominantly in the south and east (Ziguinchor, Tambacounda, Kolda regions carry the highest transmission intensity; the north around Saint-Louis is near-elimination in some zones); Sénégal has achieved impressive malaria control; case incidence declined over 80% between 2000 and the early 2020s through aggressive ITN, indoor residual spraying, and seasonal malaria chemoprevention (SMC) programmes; making Sénégal a global reference for malaria control success and an important implementation science laboratory for malaria elimination strategies. HIV/AIDS: Sénégal has a low generalised HIV prevalence (~0.3–0.5% of adults); remarkable for sub-Saharan Africa; but a concentrated epidemic with significantly elevated HIV rates in female sex workers (~7–10%), men who have sex with men (~20–25%), and injecting drug users; HIV-2 accounts for approximately 2–5% of HIV infections in Sénégal (the West African HIV-2 clade, naturally resistant to NNRTIs, makes Sénégal the only country in the GCT series where HIV-2 treatment research is a meaningful clinical programme). Arboviral diseases (dengue, chikungunya, Zika, West Nile) are Sénégal’s most rapidly growing infectious disease burden, with dengue becoming epidemic in urban Dakar and seasonal flaviviral outbreaks documented through IPD’s long-running surveillance network. Tuberculosis (~80–100/100,000 annual incidence), Neglected Tropical Diseases (schistosomiasis in the Senegal River Valley and Casamance; lymphatic filariasis; trachoma in the Sahel north), and a growing urban NCD burden (hypertension, T2D, cardiovascular disease in Dakar’s rapidly urbanising population) complete Sénégal’s disease landscape.
Institut Pasteur de Dakar and the Niakhar HDSS; Africa’s only yellow fever vaccine manufacturer and sub-Saharan Africa’s oldest demographic surveillance system: The Institut Pasteur de Dakar (IPD); established 1896 on the Cap-Vert peninsula and a founding member of the International Pasteur Network; is Sénégal’s most globally irreplaceable research institution and Africa’s most distinctive contribution to the global flaviviral disease research landscape. IPD’s most irreplaceable capability is its WHO-prequalified yellow fever vaccine manufacturing: IPD produces the 17D yellow fever vaccine at its Dakar facility, manufacturing approximately 1.5 million or more doses annually that are distributed across Africa and globally through WHO’s International Coordinating Group (ICG) stockpile mechanism; IPD is Africa’s only yellow fever vaccine producer and one of approximately six institutions worldwide holding WHO prequalification to manufacture 17D vaccines (alongside Bio-Manguinhos/Fiocruz in Brazil, Bharat Biotech in India, and a small number of others); this manufacturing capability took decades to build, cannot be replicated quickly, and makes IPD uniquely positioned for any yellow fever vaccine clinical development, yellow fever outbreak response research, and dose-optimisation or fractional dosing trials that require a manufacturer who can supply WHO-prequalified vaccine alongside clinical trial management infrastructure. Beyond yellow fever, IPD operates Africa’s most comprehensive flavivirus surveillance network: since the 1970s, IPD has been systematically monitoring dengue, Zika, West Nile, chikungunya, Rift Valley fever, and other arboviral diseases in Senegal and across West Africa through a network of sentinel sites, laboratory diagnostics, and molecular epidemiology programmes whose 50-year arboviral surveillance dataset is unmatched in depth for the West African flaviviral disease research context; IPD’s arboviral disease Phase I–III trial infrastructure; including BSL-3 laboratory capabilities, WHO-accredited vaccine lot-release testing, and established dengue vaccine trial experience; makes IPD the African partner of choice for Sanofi Pasteur, Takeda, and other dengue vaccine developers whose Africa Phase II–III programmes require site expertise in an institution that understands flavivirus biology from the inside. The Niakhar Health and Demographic Surveillance System (HDSS); operated by France’s Institut de Recherche pour le Développement (IRD) in Niakhar rural area of Fatick Region (central Sénégal; ~30,000 people in a defined rural Serer community); has been tracking births, deaths, migrations, and disease outcomes continuously since 1963: over 60 years of uninterrupted demographic and health surveillance making it sub-Saharan Africa’s oldest continuously running HDSS; older than Ghana’s NHRC Navrongo (1992), KHRC Kintampo (1994), Tanzania’s IHI Kilombero (1988 continuous surveillance inception), and Uganda’s NHRC comparable systems; the Niakhar HDSS has been used as the population base for research on malaria (vaccine trials; drug efficacy; SMC evaluation), childhood diarrheal disease, measles, pertussis, nutritional interventions, and reproductive health, providing the most longitudinally deep rural Francophone West African community research platform available for nested clinical trials, vaccine effectiveness studies, and implementation science research in the Sahelian demographic transition zone of central Sénégal. Together, IPD’s flavivirus manufacturing and surveillance expertise with Niakhar’s 60-year demographic depth create a research infrastructure combination that defines Sénégal’s irreplaceability in Francophone West African clinical research: Africa’s only yellow fever vaccine producer combined with Africa’s oldest HDSS within a single national research ecosystem connected by the CFA franc’s Euro peg.
Institut Pasteur de Dakar and the Niakhar HDSS; Africa’s only yellow fever vaccine manufacturer and sub-Saharan Africa’s oldest demographic surveillance system: The Institut Pasteur de Dakar (IPD); established 1896 on the Cap-Vert peninsula and a founding member of the International Pasteur Network; is Sénégal’s most globally irreplaceable research institution and Africa’s most distinctive contribution to the global flaviviral disease research landscape. IPD’s most irreplaceable capability is its WHO-prequalified yellow fever vaccine manufacturing: IPD produces the 17D yellow fever vaccine at its Dakar facility, manufacturing approximately 1.5 million or more doses annually that are distributed across Africa and globally through WHO’s International Coordinating Group (ICG) stockpile mechanism; IPD is Africa’s only yellow fever vaccine producer and one of approximately six institutions worldwide holding WHO prequalification to manufacture 17D vaccines (alongside Bio-Manguinhos/Fiocruz in Brazil, Bharat Biotech in India, and a small number of others); this manufacturing capability took decades to build, cannot be replicated quickly, and makes IPD uniquely positioned for any yellow fever vaccine clinical development, yellow fever outbreak response research, and dose-optimisation or fractional dosing trials that require a manufacturer who can supply WHO-prequalified vaccine alongside clinical trial management infrastructure. Beyond yellow fever, IPD operates Africa’s most comprehensive flavivirus surveillance network: since the 1970s, IPD has been systematically monitoring dengue, Zika, West Nile, chikungunya, Rift Valley fever, and other arboviral diseases in Senegal and across West Africa through a network of sentinel sites, laboratory diagnostics, and molecular epidemiology programmes whose 50-year arboviral surveillance dataset is unmatched in depth for the West African flaviviral disease research context; IPD’s arboviral disease Phase I–III trial infrastructure; including BSL-3 laboratory capabilities, WHO-accredited vaccine lot-release testing, and established dengue vaccine trial experience; makes IPD the African partner of choice for Sanofi Pasteur, Takeda, and other dengue vaccine developers whose Africa Phase II–III programmes require site expertise in an institution that understands flavivirus biology from the inside. The Niakhar Health and Demographic Surveillance System (HDSS); operated by France’s Institut de Recherche pour le Développement (IRD) in Niakhar rural area of Fatick Region (central Sénégal; ~30,000 people in a defined rural Serer community); has been tracking births, deaths, migrations, and disease outcomes continuously since 1963: over 60 years of uninterrupted demographic and health surveillance making it sub-Saharan Africa’s oldest continuously running HDSS; older than Ghana’s NHRC Navrongo (1992), KHRC Kintampo (1994), Tanzania’s IHI Kilombero (1988 continuous surveillance inception), and Uganda’s NHRC comparable systems; the Niakhar HDSS has been used as the population base for research on malaria (vaccine trials; drug efficacy; SMC evaluation), childhood diarrheal disease, measles, pertussis, nutritional interventions, and reproductive health, providing the most longitudinally deep rural Francophone West African community research platform available for nested clinical trials, vaccine effectiveness studies, and implementation science research in the Sahelian demographic transition zone of central Sénégal. Together, IPD’s flavivirus manufacturing and surveillance expertise with Niakhar’s 60-year demographic depth create a research infrastructure combination that defines Sénégal’s irreplaceability in Francophone West African clinical research: Africa’s only yellow fever vaccine producer combined with Africa’s oldest HDSS within a single national research ecosystem connected by the CFA franc’s Euro peg.
Sénégal’s research proposition is unique in the series: IPD’s yellow fever vaccine manufacturing and flavivirus surveillance (Africa’s only YF producer; 50+ year arboviral dataset), the CFA franc’s Euro peg eliminating currency risk entirely for EUR-denominated sponsors, the Niakhar HDSS’s 60-year rural Francophone West African demographic depth, and Dakar’s direct Paris connectivity; all within a French-language regulatory environment that doubles as the operational framework for the entire Francophone West African research corridor of 16+ countries.
Direction de la Pharmacie, des Laboratoires et du Médicament (DPLM) clinical trial authorisation under French-aligned pharmaceutical law and ICH GCP E6(R2)/WHO GCP standards; Comité National d’Éthique pour la Recherche en Santé (CNERS) national ethics review; institutional ethics committees at UCAD, IPD, Hôpital Fann, and regional hospitals; all regulatory submissions in French; directly portable to 15+ other Francophone West/Central African regulatory authorities with minimal adaptation; DPLM approval timelines approximately 3–6 months; Sénégal’s institutional stability through democratic transitions ensures regulatory continuity; DPLM engaged with UEMOA pharmaceutical harmonisation framework.
XOF pegged to EUR at 655.957 (irrevocable since 1999; France Treasury guarantee) gives EUR-denominated sponsors zero currency risk; completely unique in sub-Saharan Africa; no hedging costs; perfect operational cost predictability for multi-year Phase III programmes; USD-denominated sponsors face only EUR/USD exposure (modest; hedgeable); Dakar’s direct daily Air France Paris connections (6h) and additional European routes (Brussels; Lisbon; Casablanca) making Sénégal the most European-accessible sub-Saharan African research market; French pharmaceutical sector (Sanofi, Institut Mérieux, Servier, Ipsen) has established Senegalese research partnerships precisely because of language and currency alignment.
18M with seasonal malaria (~3–4M cases; south/east high transmission; SMC pioneer; validation site for WHO-recommended seasonal chemoprevention); HIV concentrated epidemic (~0.3–0.5% general; FSW ~10%; MSM ~20–25%); HIV-2 (~2–5% of HIV; West Africa’s specific clade; NNRTI-naturally resistant; unique treatment research); arboviral diseases (dengue epidemic in Dakar; chikungunya; Zika; West Nile; IPD’s 50-year surveillance); Niakhar HDSS 60yr (Serer rural community; malaria; vaccine; nutrition); TB (~80–100/100,000); NTDs (schistosomiasis; filariasis; trachoma); urban NCD (hypertension; T2D growing in Dakar); Sahelian pharmacogenomics (Wolof, Fula, Serer).
IPD (Dakar; 1896; International Pasteur Network; yellow fever vaccine manufacture; flavivirus BSL-3; dengue/Zika/YF Phase I–III); Niakhar HDSS/IRD (Fatick; 60yr; sub-Saharan Africa’s oldest HDSS; malaria; vaccine; nutrition); Hôpital Fann/CHNU (UCAD; national referral; SMIT tropical medicine; HIV; infectious disease); IRESSEF (national health research institute; COVID-19; emerging pathogens; Africa CDC partner); UCAD Faculty of Medicine (medical education; investigator pipeline); French-language regulatory portal for 16+ Francophone West/Central African markets; growing Dakar CRO ecosystem (IQVIA, ICON, Parexel French-language West Africa operations).
Direction de la Pharmacie, des Laboratoires et du Médicament (DPLM) clinical trial authorisation under French-aligned pharmaceutical law and ICH GCP E6(R2)/WHO GCP standards; Comité National d’Éthique pour la Recherche en Santé (CNERS) national ethics review; institutional ethics committees at UCAD, IPD, Hôpital Fann, and regional hospitals; all regulatory submissions in §§French§§; directly portable to 15+ other Francophone West/Central African regulatory authorities with minimal adaptation; DPLM approval timelines approximately 3–6 months; Sénégal’s institutional stability through democratic transitions ensures regulatory continuity; DPLM engaged with UEMOA pharmaceutical harmonisation framework.
XOF pegged to EUR at 655.957 (irrevocable since 1999; France Treasury guarantee) gives EUR-denominated sponsors §§zero currency risk§§; completely unique in sub-Saharan Africa; no hedging costs; perfect operational cost predictability for multi-year Phase III programmes; USD-denominated sponsors face only EUR/USD exposure (modest; hedgeable); Dakar’s direct daily Air France Paris connections (6h) and additional European routes (Brussels; Lisbon; Casablanca) making Sénégal the most European-accessible sub-Saharan African research market; French pharmaceutical sector (Sanofi, Institut Mérieux, Servier, Ipsen) has established Senegalese research partnerships precisely because of language and currency alignment.
18M with seasonal malaria (~3–4M cases; south/east high transmission; SMC pioneer; validation site for WHO-recommended seasonal chemoprevention); HIV concentrated epidemic (~0.3–0.5% general; FSW ~10%; MSM ~20–25%); §§HIV-2§§ (~2–5% of HIV; West Africa’s specific clade; NNRTI-naturally resistant; unique treatment research); arboviral diseases (dengue epidemic in Dakar; chikungunya; Zika; West Nile; IPD’s 50-year surveillance); Niakhar HDSS 60yr (Serer rural community; malaria; vaccine; nutrition); TB (~80–100/100,000); NTDs (schistosomiasis; filariasis; trachoma); urban NCD (hypertension; T2D growing in Dakar); Sahelian pharmacogenomics (Wolof, Fula, Serer).
IPD (Dakar; 1896; International Pasteur Network; yellow fever vaccine manufacture; flavivirus BSL-3; dengue/Zika/YF Phase I–III); Niakhar HDSS/IRD (Fatick; 60yr; sub-Saharan Africa’s oldest HDSS; malaria; vaccine; nutrition); Hôpital Fann/CHNU (UCAD; national referral; SMIT tropical medicine; HIV; infectious disease); IRESSEF (national health research institute; COVID-19; emerging pathogens; Africa CDC partner); UCAD Faculty of Medicine (medical education; investigator pipeline); French-language regulatory portal for 16+ Francophone West/Central African markets; growing Dakar CRO ecosystem (IQVIA, ICON, Parexel French-language West Africa operations).
Arboviral and flaviviral diseases; Sénégal’s most globally irreplaceable research pillar; are anchored by IPD’s unique dual manufacturing and clinical research capability: IPD’s status as Africa’s only WHO-prequalified yellow fever vaccine producer means that yellow fever vaccine fractional dosing trials (WHO is exploring whether 1/5-dose fractional dosing can stretch the global stockpile during shortage emergencies, a strategy partly validated in Sénégal), yellow fever vaccine co-administration studies (with other EPI vaccines in Sénégal’s immunisation programme), and next-generation YF vaccine development all require IPD as the African institutional partner whose manufacturing expertise, WHO accreditation, and lot-release testing capability are concentrated in a single site that has produced YF vaccine since the 1940s; for any sponsor whose regulatory submission requires African Phase I–III data on a flaviviral vaccine or therapeutic, IPD’s integrated manufacturing-and-research capability in Dakar is the only African option. Dengue; the most commercially important emerging arboviral disease for the pharmaceutical industry; is the second major therapeutic pillar: IPD’s 50-year dengue surveillance network, its molecular diagnostics for dengue serotyping, and Sénégal’s evolving dengue epidemic (urban Dakar dengue has become a significant outbreak concern, with all four DENV serotypes circulating) together make Senegal the African anchor site for dengue vaccine Phase II–III trials (Sanofi’s CYD-TDV dengue vaccine and Takeda’s TAK-003 dengue vaccine both had African components with IPD involvement), next-generation monovalent dengue vaccines, and dengue therapeutics requiring African flavivirus ecology data. Malaria implementation science; Sénégal’s second defining research contribution; is specifically about malaria elimination strategy rather than the high-transmission malaria ecology of the series’ East African countries (Kenya, Tanzania, Uganda): Sénégal’s dramatic malaria decline and its ongoing push toward elimination in northern districts make it the ideal site for malaria elimination tools (reactive case detection; mass drug administration; vector surveillance systems; malaria rapid diagnostic test validation in low-transmission settings where test performance characteristics differ from high-transmission contexts), seasonal malaria chemoprevention (SMC) next-generation drug combination trials, and implementation science for translating malaria control success into elimination; a research niche distinct from and complementary to Kenya’s KEMRI-Wellcome Trust’s high-transmission malaria immunology and Tanzania’s IHI Kilombero’s vector control ecology. HIV concentrated epidemic research; including HIV prevention in female sex workers and MSM, HIV-2 pharmacology, and the legendary ISAARV initiative’s legacy in early ART implementation; provides Sénégal’s third pillar; the SMIT (Service des Maladies Infectieuses et Tropicales) at Hôpital Fann has been conducting HIV and tropical medicine research since the 1980s and is Senegal’s primary institutional memory for tropical infectious disease clinical research. The Francophone West Africa gateway function; French-language regulatory submissions from Dakar that can be adapted for DPLM-equivalent authorities across Côte d’Ivoire, Burkina Faso, Mali, Niger, Guinea, and Benin; creates a specific commercial service that Sénégal provides to pan-Francophone-African research portfolios that no English-language West African research market (Nigeria, Ghana) can replicate.
Sénégal’s research geography is Dakar-concentrated; IPD, Hôpital Fann/CHNU, Hôpital Principal, IRESSEF, and the children’s hospitals forming the capital’s integrated research cluster; with Niakhar/Fatick (IRD’s 60-year HDSS field site), Thiès (second city; malaria research), Ziguinchor (Casamance; high malaria; HIV), and Saint-Louis (north; near-elimination malaria) providing geographic coverage of Sénégal’s distinct epidemiological corridors from near-elimination Sahel north through active malaria south.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Institut Pasteur de Dakar (IPD) | Dakar | Africa’s most historically distinguished flaviviral disease research institution; established 1896, producing the WHO-prequalified 17D yellow fever vaccine and operating one of West Africa’s most comprehensive arboviral disease surveillance networks; with Phase I–III clinical trial capability across yellow fever vaccine (fractional dosing trials; co-administration studies; next-generation YF vaccine candidates), dengue vaccines and therapeutics (all 4 DENV serotypes circulating in Sénégal; IPD’s Phase II–III dengue trial experience includes Sanofi and Takeda partnerships), Zika virus (IPD identified and sequenced early West African Zika strains), West Nile virus, chikungunya, COVID-19 vaccines (IPD conducted Phase II–III COVID-19 vaccine trials during the pandemic through the African Centres for Disease Control and Prevention’s PAVIA network), malaria (vaccine immunology; drug trials through Niakhar HDSS and Dakar urban sites), HIV, and emerging pathogens; IPD’s BSL-3 laboratory infrastructure, WHO lot-release testing accreditation, and International Pasteur Network governance; including Paris Institut Pasteur’s institutional oversight; provide the research quality credentialing that FDA, EMA, and WHO reviewers accept for vaccine clinical data from sub-Saharan Africa without additional data quality questions; the world’s most important single African institution for yellow fever, dengue, and West African flaviviral disease product development and licensing. |
| 02 | Hôpital Fann / CHNU de Fann; UCAD | Dakar | Sénégal’s primary national teaching and referral hospital; affiliated with the Université Cheikh Anta Diop de Dakar (UCAD) and housing the §§Service des Maladies Infectieuses et Tropicales (SMIT)§§, one of West Africa’s most important tropical disease clinical research units; with Phase I–IV research across HIV/AIDS (SMIT has been conducting HIV research since the epidemic’s emergence in Senegal in the 1980s; the ISAARV initiative; one of Africa’s first ART programmes (1998), described in AIDS and NEJM letters; was launched from SMIT; HIV-2 treatment research; concentrated epidemic key population research through SMIT’s longstanding PEPFAR and ANRS-funded partnerships), tropical medicine (trypanosomiasis; leishmaniasis; dengue; tropical neurological infections), TB (pulmonary medicine; MDR-TB), and internal medicine; SMIT’s ANRS | Maladies infectieuses émergentes (French agency) partnership creates the French government research funding and regulatory documentation framework that makes SMIT the primary entry point for French pharmaceutical company (Sanofi, Servier) clinical research activations in Sénégal; UCAD’s Faculty of Medicine provides Sénégal’s primary GCP-trained clinical investigator pipeline; Hôpital Fann’s CNERS ethics committee provides the most experienced research ethics review in Sénégal for complex HIV, tropical medicine, and infectious disease trial protocols. |
| 03 | Niakhar Research Site; IRD HDSS | Niakhar, Fatick Region | Sub-Saharan Africa’s oldest continuously running Health and Demographic Surveillance System; operated by France’s §§Institut de Recherche pour le Développement (IRD)§§ in the Niakhar rural area of Fatick Region (central Sénégal; predominantly Serer farming community; approximately 30,000 people in a defined geographic area ~150km east of Dakar); tracking births, deaths, migrations, and disease outcomes without interruption since §§1963§§; the Niakhar HDSS’s 60-year longitudinal record has provided the research infrastructure for: malaria drug efficacy and vaccine studies (the first Senegalese malaria vaccine trials used Niakhar’s demographic surveillance as the population framework); childhood diarrheal disease intervention trials; measles and pertussis epidemiology and vaccine effectiveness; nutritional intervention studies; SMC (seasonal malaria chemoprevention) effectiveness evaluation; and family planning research; the IRD’s French institutional governance; including IRD ethics committee review and French National Research Agency (ANR) grant management standards; provides the French academic research governance that French and European pharmaceutical sponsors require for clinical data from Sénégal’s rural research sites; for sponsors designing nested clinical trials within a pre-existing deeply characterised rural Francophone West African demographic cohort, Niakhar HDSS is the only option of comparable longitudinal depth in the Sahel transition zone research ecology that characterises much of West Africa’s disease burden. |
| 04 | IRESSEF; Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation | Dakar | Sénégal’s national health research institute; established 2020 to coordinate and strengthen national health research, epidemiological surveillance, and research capacity building; with Phase II–III research activity across COVID-19 vaccines and therapeutics (IRESSEF was a key African site for COVID-19 vaccine trials through the African CDC’s PAVIA network and the Coalition for Epidemic Preparedness Innovations (CEPI) partnerships), malaria (SMC research; diagnostic validation; malaria genomics), arboviral disease surveillance and clinical research (in collaboration with IPD), HIV surveillance (national seroprevalence and molecular epidemiology studies), and emerging pathogen preparedness (monkeypox; Lassa fever; influenza); IRESSEF’s Africa CDC partnership positions it as Sénégal’s primary entry point for pan-African regulatory harmonisation research and as the institutional interface between Sénégal’s national research priorities and the Africa CDC’s continental health security agenda; for sponsors conducting research that requires alignment with Africa CDC’s regulatory harmonisation framework (African Medicines Agency processes), IRESSEF’s national institute status and Africa CDC partnership create the institutional gateway that IPD’s more vaccine-specific mandate cannot fulfil. |
| 05 | Hôpital Principal de Dakar | Dakar | Dakar’s highest-technical-level hospital; historically Sénégal’s primary military hospital now serving both military and civilian populations as a public teaching institution with the most advanced diagnostic infrastructure in Sénégal; with Phase II–III research activity across cardiovascular (Hôpital Principal’s cardiology and cardiac surgery departments are among West Africa’s most technically equipped; cardiovascular NCD research growing in Dakar’s urbanising population), oncology (Sénégal’s primary cancer centre; cervical cancer; prostate cancer; elevated in West African men; breast cancer), internal medicine, and infectious disease; Hôpital Principal’s UCAD affiliation through the Faculty of Medicine and its established pharmaceutical company research relationship; particularly with French pharmaceutical companies whose historical ties to Dakar’s colonial-era medical infrastructure create long-standing research partnerships; provide an important complementary research site to Hôpital Fann’s SMIT-focused infectious disease specialisation for sponsors designing multi-site Dakar Phase III programs in cardiovascular, oncology, or non-infectious NCD therapeutic areas. |
| 06 | Hôpital de l’Enfant Albert Royer | Dakar | Sénégal’s national paediatric referral hospital; affiliated with UCAD’s Faculty of Medicine and receiving paediatric referrals from across Sénégal’s 14 regions; with Phase II–IV paediatric research across malaria (childhood malaria is the dominant paediatric disease burden in Sénégal; Albert Royer’s paediatric malaria programme conducts vaccine efficacy and antimalarial drug trials in children), paediatric HIV (Sénégal’s PMTCT programme and paediatric ARV pharmacokinetics studies), nutrition (stunting and wasting research; nutritional supplementation trials; Sénégal’s groundnut belt’s nutritional epidemiology), paediatric vaccines (EPI vaccine co-administration research; pneumococcal conjugate vaccine effectiveness; rotavirus; meningococcal meningitis in the Sahel meningitis belt’s northern interface), and neonatal medicine; Albert Royer’s national paediatric referral mandate creates the patient concentration; across the full spectrum of Sénégal’s childhood disease burden from malaria to malnutrition to neonatal infections; that makes it Sénégal’s essential institutional partner for sponsors requiring paediatric Phase II–IV vaccine, antimalarial, nutritional, and antibiotic trial data from Francophone West Africa’s most established paediatric research institution. |
| 07 | Centre Hospitalier Régional de Thiès | Thiès | Sénégal’s second-largest city hospital; in Thiès (~500K), the country’s main inland transport hub and agricultural processing centre 70km east of Dakar; with Phase II–III research activity across malaria (Thiès Region’s central position between Dakar’s low-transmission peri-urban context and the higher-transmission south creates a research environment for malaria interventions at moderate transmission intensity), HIV, TB, and NCD; the Institut de Recherche pour le Développement (IRD) has historically operated research programmes through Thiès in addition to the Niakhar HDSS field site, creating a broader Thiès-Niakhar central Senegalese research corridor that links urban Thiès’s clinical infrastructure with Niakhar’s rural HDSS demographic depth; for sponsors designing multi-site Sénégal malaria or vaccine trials whose design requires both rural HDSS nested enrollment (through Niakhar) and urban hospital-based clinical enrollment (through Thiès Regional Hospital) within a single central Senegalese research network, Thiès Regional Hospital’s proximity to Niakhar (~30km) makes it the natural hospital research partner for IRD’s Niakhar field operations. |
| 08 | Centre Hospitalier Régional de Ziguinchor | Ziguinchor, Casamance | Southern Sénégal’s primary hospital; in Ziguinchor, the capital of the Casamance region that is geographically separated from northern Sénégal by The Gambia; with Phase II–III research activity across malaria (the Casamance region carries Sénégal’s highest malaria transmission intensity; its wetter, more tropical ecology creates higher and more prolonged annual malaria transmission than the Sahel-transition zones further north; for sponsors requiring high-transmission malaria enrollment in Sénégal, Ziguinchor’s Casamance catchment is the southern Senegalese equivalent of northern Ghana’s or southern Uganda’s high-transmission research environments), HIV (Casamance’s cross-border mobility with Guinea-Bissau creates specific HIV-2 epidemiology research access in a border region where HIV-2 is more prevalent than in Dakar), and tropical medicine; Ziguinchor’s distinct Jola/Diola cultural context; the Casamance region’s indigenous communities having historical separatist tensions with Dakar; requires culturally sensitive community engagement approaches that IRESSEF and IPD have developed through long-standing Casamance research partnerships. |
| 09 | Centre Hospitalier Régional de Saint-Louis | Saint-Louis | Northern Sénégal’s primary hospital; in Saint-Louis (UNESCO World Heritage historic colonial capital on the Senegal River near the Mauritanian border), the most historically significant city in Sénégal and the capital of the first French West African territory; with Phase II–III research activity across malaria (Saint-Louis Region represents Sénégal’s near-elimination malaria zone; the PNLP has achieved very low malaria incidence rates in some Saint-Louis districts through aggressive control, making it one of Africa’s most important sites for malaria elimination strategy research; testing tools designed for the “last mile” of malaria elimination including reactive case detection, mass drug administration, and serological surveillance for malaria elimination monitoring), schistosomiasis (the Senegal River Valley carries S. haematobium and S. mansoni in the irrigated agricultural communities along the river; creating a specific schistosomiasis research platform in northern Senegal’s Sahelo-Sudanian river ecology), and nutrition; Saint-Louis’s near-elimination malaria context makes it the most commercially important site in Sénégal for sponsors developing malaria elimination tools whose effectiveness must be demonstrated in low-transmission settings. |
| 10 | Centre Hospitalier Régional de Kaolack | Kaolack | Central Sénégal’s primary hospital; in Kaolack, the groundnut basin’s commercial hub at the crossroads of routes connecting Dakar to the south and east of Sénégal and to The Gambia; with Phase II–III research activity across malaria (Kaolack Region’s moderate seasonal malaria transmission in the groundnut basin transition zone between low-transmission Dakar environs and high-transmission Casamance), HIV (Kaolack’s transport crossroads and commercial sex economy create elevated HIV risk in specific populations), nutrition (the groundnut basin’s agricultural economy and seasonal food insecurity create nutritional research populations), and NCD; Kaolack Regional Hospital’s central location; making it a natural research hub for the densely populated Wolof groundnut basin of central Sénégal (the country’s agricultural heartland with some of its most concentrated rural populations); provides geographic research coverage of the central corridor connecting Dakar to the south for sponsors designing multi-site Sénégal programmes requiring the groundnut basin’s distinct peri-urban and rural agricultural community demographics alongside Dakar’s urban and Ziguinchor’s high-malaria southern research environments. |
| 11 | Hôpital Régional de Tambacounda | Tambacounda | Eastern Sénégal’s primary hospital; in Tambacounda, the gateway to Sénégal’s remote eastern regions bordering Mali and Guinea; with Phase II–III research activity across malaria (Tambacounda Region carries some of Sénégal’s highest malaria transmission intensities; comparable to Ziguinchor in the south; the Gambia River tributary zones of eastern Sénégal’s Tambacounda Region create sustained wet-season malaria transmission that is among the most intense in Sénégal’s northern ecological zones; making Tambacounda Hospital a high-transmission malaria complement to Ziguinchor’s southern high-transmission corridor), neglected tropical diseases (the remote eastern regions of Sénégal carry trypanosomiasis risk in the tsetse-belt zones bordering Guinea; lymphatic filariasis; onchocerciasis in some riverine areas), and TB; Tambacounda’s remote eastern location; approximately 470km from Dakar; creates operational challenges for sponsor monitoring that IRESSEF and IPD field teams have experience managing through mobile research team protocols developed for Sénégal’s geographically dispersed national research network. |
| 12 | Hôpital Dalal Jamm; CHUN | Dakar (Guédiawaye) | Dakar’s newest major academic hospital; the Centre Hospitalier Universitaire National de Dalal Jamm (“good health” in Wolof), opened in 2012 in Guédiawaye on Dakar’s northern suburban periphery, serving the periurban populations of Grand Dakar’s most densely inhabited suburban districts; with Phase II–III research activity across HIV, malaria, cardiovascular disease, and internal medicine; Dalal Jamm’s periurban Guédiawaye location provides research access to Dakar’s rapidly growing suburban population; where dengue transmission is active (urban and periurban Dakar carries the highest dengue exposure risk in Sénégal), HIV incidence in key populations is elevated, and the urban NCD burden (hypertension, T2D) is growing fastest in Sénégal’s middle-income expanding suburbs; creating a research demographic distinctly different from Hôpital Fann’s central Dakar referral catchment; Dalal Jamm’s UCAD affiliation through the Faculty of Medicine provides the academic governance for its growing research programme, and its periurban location creates dengue vaccine and NCD research access in the demographic zone where Dakar’s flaviviral disease burden is concentrated. |
Africa’s most historically distinguished flaviviral disease research institution; established 1896, producing the WHO-prequalified 17D yellow fever vaccine and operating one of West Africa’s most comprehensive arboviral disease surveillance networks; with Phase I–III clinical trial capability across yellow fever vaccine (fractional dosing trials; co-administration studies; next-generation YF vaccine candidates), dengue vaccines and therapeutics (all 4 DENV serotypes circulating in Sénégal; IPD’s Phase II–III dengue trial experience includes Sanofi and Takeda partnerships), Zika virus (IPD identified and sequenced early West African Zika strains), West Nile virus, chikungunya, COVID-19 vaccines (IPD conducted Phase II–III COVID-19 vaccine trials during the pandemic through the African Centres for Disease Control and Prevention’s PAVIA network), malaria (vaccine immunology; drug trials through Niakhar HDSS and Dakar urban sites), HIV, and emerging pathogens; IPD’s BSL-3 laboratory infrastructure, WHO lot-release testing accreditation, and International Pasteur Network governance; including Paris Institut Pasteur’s institutional oversight; provide the research quality credentialing that FDA, EMA, and WHO reviewers accept for vaccine clinical data from sub-Saharan Africa without additional data quality questions; the world’s most important single African institution for yellow fever, dengue, and West African flaviviral disease product development and licensing.
Sénégal’s primary national teaching and referral hospital; affiliated with the Université Cheikh Anta Diop de Dakar (UCAD) and housing the §§Service des Maladies Infectieuses et Tropicales (SMIT)§§, one of West Africa’s most important tropical disease clinical research units; with Phase I–IV research across HIV/AIDS (SMIT has been conducting HIV research since the epidemic’s emergence in Senegal in the 1980s; the ISAARV initiative; one of Africa’s first ART programmes (1998), described in AIDS and NEJM letters; was launched from SMIT; HIV-2 treatment research; concentrated epidemic key population research through SMIT’s longstanding PEPFAR and ANRS-funded partnerships), tropical medicine (trypanosomiasis; leishmaniasis; dengue; tropical neurological infections), TB (pulmonary medicine; MDR-TB), and internal medicine; SMIT’s ANRS | Maladies infectieuses émergentes (French agency) partnership creates the French government research funding and regulatory documentation framework that makes SMIT the primary entry point for French pharmaceutical company (Sanofi, Servier) clinical research activations in Sénégal; UCAD’s Faculty of Medicine provides Sénégal’s primary GCP-trained clinical investigator pipeline; Hôpital Fann’s CNERS ethics committee provides the most experienced research ethics review in Sénégal for complex HIV, tropical medicine, and infectious disease trial protocols.
Sub-Saharan Africa’s oldest continuously running Health and Demographic Surveillance System; operated by France’s §§Institut de Recherche pour le Développement (IRD)§§ in the Niakhar rural area of Fatick Region (central Sénégal; predominantly Serer farming community; approximately 30,000 people in a defined geographic area ~150km east of Dakar); tracking births, deaths, migrations, and disease outcomes without interruption since §§1963§§; the Niakhar HDSS’s 60-year longitudinal record has provided the research infrastructure for: malaria drug efficacy and vaccine studies (the first Senegalese malaria vaccine trials used Niakhar’s demographic surveillance as the population framework); childhood diarrheal disease intervention trials; measles and pertussis epidemiology and vaccine effectiveness; nutritional intervention studies; SMC (seasonal malaria chemoprevention) effectiveness evaluation; and family planning research; the IRD’s French institutional governance; including IRD ethics committee review and French National Research Agency (ANR) grant management standards; provides the French academic research governance that French and European pharmaceutical sponsors require for clinical data from Sénégal’s rural research sites; for sponsors designing nested clinical trials within a pre-existing deeply characterised rural Francophone West African demographic cohort, Niakhar HDSS is the only option of comparable longitudinal depth in the Sahel transition zone research ecology that characterises much of West Africa’s disease burden.
Sénégal’s national health research institute; established 2020 to coordinate and strengthen national health research, epidemiological surveillance, and research capacity building; with Phase II–III research activity across COVID-19 vaccines and therapeutics (IRESSEF was a key African site for COVID-19 vaccine trials through the African CDC’s PAVIA network and the Coalition for Epidemic Preparedness Innovations (CEPI) partnerships), malaria (SMC research; diagnostic validation; malaria genomics), arboviral disease surveillance and clinical research (in collaboration with IPD), HIV surveillance (national seroprevalence and molecular epidemiology studies), and emerging pathogen preparedness (monkeypox; Lassa fever; influenza); IRESSEF’s Africa CDC partnership positions it as Sénégal’s primary entry point for pan-African regulatory harmonisation research and as the institutional interface between Sénégal’s national research priorities and the Africa CDC’s continental health security agenda; for sponsors conducting research that requires alignment with Africa CDC’s regulatory harmonisation framework (African Medicines Agency processes), IRESSEF’s national institute status and Africa CDC partnership create the institutional gateway that IPD’s more vaccine-specific mandate cannot fulfil.
Dakar’s highest-technical-level hospital; historically Sénégal’s primary military hospital now serving both military and civilian populations as a public teaching institution with the most advanced diagnostic infrastructure in Sénégal; with Phase II–III research activity across cardiovascular (Hôpital Principal’s cardiology and cardiac surgery departments are among West Africa’s most technically equipped; cardiovascular NCD research growing in Dakar’s urbanising population), oncology (Sénégal’s primary cancer centre; cervical cancer; prostate cancer; elevated in West African men; breast cancer), internal medicine, and infectious disease; Hôpital Principal’s UCAD affiliation through the Faculty of Medicine and its established pharmaceutical company research relationship; particularly with French pharmaceutical companies whose historical ties to Dakar’s colonial-era medical infrastructure create long-standing research partnerships; provide an important complementary research site to Hôpital Fann’s SMIT-focused infectious disease specialisation for sponsors designing multi-site Dakar Phase III programs in cardiovascular, oncology, or non-infectious NCD therapeutic areas.
Sénégal’s national paediatric referral hospital; affiliated with UCAD’s Faculty of Medicine and receiving paediatric referrals from across Sénégal’s 14 regions; with Phase II–IV paediatric research across malaria (childhood malaria is the dominant paediatric disease burden in Sénégal; Albert Royer’s paediatric malaria programme conducts vaccine efficacy and antimalarial drug trials in children), paediatric HIV (Sénégal’s PMTCT programme and paediatric ARV pharmacokinetics studies), nutrition (stunting and wasting research; nutritional supplementation trials; Sénégal’s groundnut belt’s nutritional epidemiology), paediatric vaccines (EPI vaccine co-administration research; pneumococcal conjugate vaccine effectiveness; rotavirus; meningococcal meningitis in the Sahel meningitis belt’s northern interface), and neonatal medicine; Albert Royer’s national paediatric referral mandate creates the patient concentration; across the full spectrum of Sénégal’s childhood disease burden from malaria to malnutrition to neonatal infections; that makes it Sénégal’s essential institutional partner for sponsors requiring paediatric Phase II–IV vaccine, antimalarial, nutritional, and antibiotic trial data from Francophone West Africa’s most established paediatric research institution.
Sénégal’s second-largest city hospital; in Thiès (~500K), the country’s main inland transport hub and agricultural processing centre 70km east of Dakar; with Phase II–III research activity across malaria (Thiès Region’s central position between Dakar’s low-transmission peri-urban context and the higher-transmission south creates a research environment for malaria interventions at moderate transmission intensity), HIV, TB, and NCD; the Institut de Recherche pour le Développement (IRD) has historically operated research programmes through Thiès in addition to the Niakhar HDSS field site, creating a broader Thiès-Niakhar central Senegalese research corridor that links urban Thiès’s clinical infrastructure with Niakhar’s rural HDSS demographic depth; for sponsors designing multi-site Sénégal malaria or vaccine trials whose design requires both rural HDSS nested enrollment (through Niakhar) and urban hospital-based clinical enrollment (through Thiès Regional Hospital) within a single central Senegalese research network, Thiès Regional Hospital’s proximity to Niakhar (~30km) makes it the natural hospital research partner for IRD’s Niakhar field operations.
Southern Sénégal’s primary hospital; in Ziguinchor, the capital of the Casamance region that is geographically separated from northern Sénégal by The Gambia; with Phase II–III research activity across malaria (the Casamance region carries Sénégal’s highest malaria transmission intensity; its wetter, more tropical ecology creates higher and more prolonged annual malaria transmission than the Sahel-transition zones further north; for sponsors requiring high-transmission malaria enrollment in Sénégal, Ziguinchor’s Casamance catchment is the southern Senegalese equivalent of northern Ghana’s or southern Uganda’s high-transmission research environments), HIV (Casamance’s cross-border mobility with Guinea-Bissau creates specific HIV-2 epidemiology research access in a border region where HIV-2 is more prevalent than in Dakar), and tropical medicine; Ziguinchor’s distinct Jola/Diola cultural context; the Casamance region’s indigenous communities having historical separatist tensions with Dakar; requires culturally sensitive community engagement approaches that IRESSEF and IPD have developed through long-standing Casamance research partnerships.
Northern Sénégal’s primary hospital; in Saint-Louis (UNESCO World Heritage historic colonial capital on the Senegal River near the Mauritanian border), the most historically significant city in Sénégal and the capital of the first French West African territory; with Phase II–III research activity across malaria (Saint-Louis Region represents Sénégal’s near-elimination malaria zone; the PNLP has achieved very low malaria incidence rates in some Saint-Louis districts through aggressive control, making it one of Africa’s most important sites for malaria elimination strategy research; testing tools designed for the “last mile” of malaria elimination including reactive case detection, mass drug administration, and serological surveillance for malaria elimination monitoring), schistosomiasis (the Senegal River Valley carries S. haematobium and S. mansoni in the irrigated agricultural communities along the river; creating a specific schistosomiasis research platform in northern Senegal’s Sahelo-Sudanian river ecology), and nutrition; Saint-Louis’s near-elimination malaria context makes it the most commercially important site in Sénégal for sponsors developing malaria elimination tools whose effectiveness must be demonstrated in low-transmission settings.
Central Sénégal’s primary hospital; in Kaolack, the groundnut basin’s commercial hub at the crossroads of routes connecting Dakar to the south and east of Sénégal and to The Gambia; with Phase II–III research activity across malaria (Kaolack Region’s moderate seasonal malaria transmission in the groundnut basin transition zone between low-transmission Dakar environs and high-transmission Casamance), HIV (Kaolack’s transport crossroads and commercial sex economy create elevated HIV risk in specific populations), nutrition (the groundnut basin’s agricultural economy and seasonal food insecurity create nutritional research populations), and NCD; Kaolack Regional Hospital’s central location; making it a natural research hub for the densely populated Wolof groundnut basin of central Sénégal (the country’s agricultural heartland with some of its most concentrated rural populations); provides geographic research coverage of the central corridor connecting Dakar to the south for sponsors designing multi-site Sénégal programmes requiring the groundnut basin’s distinct peri-urban and rural agricultural community demographics alongside Dakar’s urban and Ziguinchor’s high-malaria southern research environments.
Eastern Sénégal’s primary hospital; in Tambacounda, the gateway to Sénégal’s remote eastern regions bordering Mali and Guinea; with Phase II–III research activity across malaria (Tambacounda Region carries some of Sénégal’s highest malaria transmission intensities; comparable to Ziguinchor in the south; the Gambia River tributary zones of eastern Sénégal’s Tambacounda Region create sustained wet-season malaria transmission that is among the most intense in Sénégal’s northern ecological zones; making Tambacounda Hospital a high-transmission malaria complement to Ziguinchor’s southern high-transmission corridor), neglected tropical diseases (the remote eastern regions of Sénégal carry trypanosomiasis risk in the tsetse-belt zones bordering Guinea; lymphatic filariasis; onchocerciasis in some riverine areas), and TB; Tambacounda’s remote eastern location; approximately 470km from Dakar; creates operational challenges for sponsor monitoring that IRESSEF and IPD field teams have experience managing through mobile research team protocols developed for Sénégal’s geographically dispersed national research network.
Dakar’s newest major academic hospital; the Centre Hospitalier Universitaire National de Dalal Jamm (“good health” in Wolof), opened in 2012 in Guédiawaye on Dakar’s northern suburban periphery, serving the periurban populations of Grand Dakar’s most densely inhabited suburban districts; with Phase II–III research activity across HIV, malaria, cardiovascular disease, and internal medicine; Dalal Jamm’s periurban Guédiawaye location provides research access to Dakar’s rapidly growing suburban population; where dengue transmission is active (urban and periurban Dakar carries the highest dengue exposure risk in Sénégal), HIV incidence in key populations is elevated, and the urban NCD burden (hypertension, T2D) is growing fastest in Sénégal’s middle-income expanding suburbs; creating a research demographic distinctly different from Hôpital Fann’s central Dakar referral catchment; Dalal Jamm’s UCAD affiliation through the Faculty of Medicine provides the academic governance for its growing research programme, and its periurban location creates dengue vaccine and NCD research access in the demographic zone where Dakar’s flaviviral disease burden is concentrated.
Sénégal’s pharmaceutical regulatory authority; the Direction de la Pharmacie, des Laboratoires et du Médicament under the Ministry of Health and Social Action; governing pharmaceutical product registration, clinical trial authorisation, and GCP compliance under French-aligned pharmaceutical law consistent with ICH GCP E6(R2) and WHO GCP standards; all regulatory submissions are in French; directly transferable to other Francophone West/Central African regulatory authorities with minimal adaptation, creating the regulatory economy of scale that makes Senegal the natural headquarters for pan-Francophone African research designs; DPLM approval timelines approximately 3–6 months for standard Phase II–III applications; DPLM engaged with UEMOA pharmaceutical harmonisation and the African Medicines Regulatory Harmonisation (AMRH) framework; Sénégal’s consistent democratic governance ensures DPLM institutional continuity.
Sénégal’s national health research ethics committee; providing national-level ethics review for all health research involving human subjects in Sénégal, alongside institutional ethics committees at UCAD, IPD, Hôpital Fann, and IRESSEF; whose review process is conducted entirely in French and is aligned with international research ethics standards (Declaration of Helsinki; CIOMS guidelines); CNERS approval is required alongside DPLM clinical trial authorisation for all commercial pharmaceutical company Phase II–III programmes; CNERS’s 30+ year track record reviewing IPD’s vaccine trial protocols, UCAD/SMIT’s HIV research ethics applications, and IRD’s Niakhar HDSS-nested study protocols provides Sénégal’s most experienced French-language research ethics review process for flaviviral disease, vaccine, HIV, and tropical medicine trials.
Sénégal’s national health research coordination institute; established 2020, partnered with the Africa CDC, and coordinating national health research priorities including COVID-19 vaccine trials, emerging pathogen surveillance, malaria control research, and HIV monitoring; providing the institutional interface between Sénégal’s national public health research agenda and international sponsor research programmes; IRESSEF’s Africa CDC partnership positions it as the national institute whose regulatory engagement enables alignment between commercial Phase II–III programmes and Africa CDC’s African Medicines Agency (AMA) harmonisation agenda, making IRESSEF an increasingly important institutional partner for sponsors designing African research portfolios that must engage with the AMA’s emerging pan-African regulatory framework.
Africa’s most historically important flaviviral disease research institution; established 1896, WHO-prequalified yellow fever vaccine manufacturer, International Pasteur Network member; conducting Phase I–III research across yellow fever vaccines (fractional dosing; co-administration; next-generation YF candidates), dengue (all 4 DENV serotypes; Phase II–III dengue vaccine trials; molecular diagnostics), Zika, West Nile, chikungunya, COVID-19, malaria, and HIV through BSL-3 laboratory infrastructure and WHO-accredited vaccine lot-release testing; IPD’s Paris Institut Pasteur institutional governance provides the French academic research quality standards that FDA and EMA accept for vaccine clinical data from West Africa; Africa’s only institution simultaneously producing a WHO-prequalified flaviviral vaccine and conducting Phase I–III flaviviral disease clinical trials; a uniquely integrated vaccine manufacturing-and-research capability whose regulatory implications for flaviviral disease product development are global in scope.
France’s development-focused research institution; whose Niakhar HDSS operations in Fatick Region since 1963 have created sub-Saharan Africa’s oldest continuously running demographic surveillance system; providing the longitudinal rural Francophone West African community health research platform (60+ years of births, deaths, disease outcomes, and behavioural data in a defined Serer farming community) that underpins Sénégal’s most distinctive demographic research credential; IRD’s French institutional governance; National Research Agency (ANR) grant management; IRD ethics committee review; French academic research quality standards; provides the European academic research credentialing for Niakhar HDSS-nested clinical trials analogous to IHI’s Swiss TPH governance in Tanzania and AHRI’s Norwegian-Swedish governance in Ethiopia; the Niakhar HDSS is irreplaceable for nested malaria, vaccine, and nutrition trials requiring a pre-characterised rural Francophone West African demographic cohort with 60 years of continuous baseline data.
Sénégal’s primary university; named after the Pan-African historian Cheikh Anta Diop; whose Faculty of Medicine and Faculty of Pharmacy train Sénégal’s physicians, pharmacists, and research scientists and produce Sénégal’s GCP-trained clinical investigator pipeline; UCAD’s research partnerships with the Institut Pasteur Paris network, IRD, ANRS | MIE, and French universities (Bordeaux, Paris VI) create the French academic governance channels through which Sénégal’s clinical research portfolio gains international scientific credibility for European regulatory submissions; UCAD’s affiliated hospital research programme at Hôpital Fann (SMIT), Hôpital Albert Royer (paediatrics), and Hôpital Principal (cardiovascular; oncology) provides the academic investigator community spanning the full range of Sénégal’s research-active therapeutic areas.
Sénégal’s national health research coordination institution; established 2020 and growing rapidly as the institutional bridge between Sénégal’s existing research infrastructure (IPD, UCAD, IRD Niakhar) and new international research partnerships; conducting COVID-19 vaccine and therapeutics research (through CEPI and Africa CDC PAVIA partnerships), malaria surveillance and intervention research, arboviral disease epidemiology (in collaboration with IPD), and health systems research; IRESSEF’s institutional position as a government-backed national research institute; affiliated with the Ministry of Health; gives it a regulatory navigation role for commercial sponsors that IPD’s more specialised vaccine mandate and UCAD’s university status do not fully cover; the emerging institutional hub for sponsors whose Sénégal research programme requires coordination with Sénégal’s national public health priorities alongside commercial Phase II–III trial activation.
Global CRO with Sénégal operations managed through its Francophone West Africa network; based in Dakar with field teams at Niakhar HDSS sites and regional hospitals; supporting Phase II–IV programs in French across arboviral diseases (IPD yellow fever and dengue vaccine platforms), malaria (SMC trials; vaccine research at Niakhar and regional hospital sites), HIV (SMIT Hôpital Fann; key population research), TB, NTDs, and NCD; DPLM regulatory submission expertise and CNERS ethics application navigation in French; XOF/EUR budget management (zero currency risk); Dakar hub coordination for pan-Francophone West Africa multi-country programmes spanning Sénégal, Côte d’Ivoire, Burkina Faso, Guinea, and Benin; French-language CRO operations serving European pharmaceutical company research teams.
International CRO with Sénégal operations supporting Phase II–IV arboviral disease (IPD flavivirus platform; dengue vaccine trials), malaria (Niakhar HDSS nested trials; Ziguinchor and Tambacounda high-transmission sites; Saint-Louis near-elimination studies), HIV (SMIT Hôpital Fann; concentrated epidemic key population research), and paediatric vaccine programs; French-language regulatory strategy for DPLM submissions and pan-Francophone African regulatory adaptation; XOF/EUR budget management; Francophone West Africa regional coordination integrating Sénégal with Côte d’Ivoire, Mali, and Burkina Faso within pan-Francophone malaria, dengue, and NTD Phase III programs.
Global CRO with Sénégal operations providing Phase II–III trial management and DPLM regulatory strategy in French across arboviral disease, malaria, HIV, NTDs, paediatric vaccines, and NCD indications; established site networks across Dakar (IPD, Hôpital Fann/SMIT, Hôpital Albert Royer, IRESSEF, Hôpital Principal, Dalal Jamm), Niakhar HDSS rural field sites, Thiès Regional Hospital, Ziguinchor (Casamance), Saint-Louis, Kaolack, and Tambacounda; biostatistics and data management for Senegalese multi-ethnic pharmacogenomic sub-studies across Wolof, Fula, and Serer population groups; pan-Francophone West Africa programme coordination.
International biopharmaceutical solutions company with Sénégal operations providing integrated Phase I–IV clinical development services in French across arboviral disease (IPD yellow fever and dengue platforms), malaria (Niakhar HDSS; SMC evaluation; near-elimination Saint-Louis), HIV (key populations; HIV-2 pharmacology through SMIT UCAD), paediatric vaccines, and NTDs; XOF/EUR budget management exploiting CFA franc Euro peg for European sponsor cost predictability; pan-Francophone West Africa programme coordination integrating Sénégal’s IPD flavivirus platform and Niakhar HDSS demographic depth with Côte d’Ivoire’s larger French-speaking HIV and NCD research market for sponsors building comprehensive Francophone West African regulatory portfolios.
The Bottom Line: Sénégal is Francophone West Africa’s clinical research capital; the country where three genuinely irreplaceable research assets converge: Africa’s only yellow fever vaccine manufacturer (IPD), sub-Saharan Africa’s oldest continuous demographic surveillance system (Niakhar HDSS; 60+ years), and sub-Saharan Africa’s only Euro-pegged currency (CFA franc; zero currency risk for EUR-denominated sponsors); within a French-language regulatory framework that doubles as the operational portal for Francophone West and Central Africa’s 16-country research corridor of over 400 million people. The IPD argument is Sénégal’s most globally irreplaceable: IPD is one of approximately six institutions worldwide holding WHO prequalification to manufacture the 17D yellow fever vaccine, and it is the ONLY African institution among them; a manufacturing capability that took more than 70 years to build and cannot be replicated on any commercially relevant timeline; for any sponsor developing yellow fever vaccines (fractional dosing studies; new adjuvants; thermostable formulations; co-administration with other EPI vaccines), dengue vaccines (IPD’s 50-year dengue surveillance, all-four-serotype molecular diagnostics, and Phase II–III dengue vaccine trial experience make it the African dengue research anchor for Sanofi, Takeda, and their competitors), or any other flaviviral disease product requiring African Phase I–III data, IPD is the non-negotiable African partner whose flaviviral manufacturing expertise, WHO accreditation, BSL-3 infrastructure, and International Pasteur Network governance are assembled at no other African institution. The Niakhar argument is Sénégal’s most scientifically distinctive demographic credential in the GCT series: 60+ years of continuous IRD-operated demographic surveillance in a defined rural Senegalese community; older than every other HDSS mentioned in the series; whose uninterrupted longitudinal record of births, deaths, migrations, and disease outcomes in the same geographic cohort provides the Sahelian West African equivalent of the research depth that Uganda’s Rakai cohort provides for East African HIV science and that Ghana’s NHRC Navrongo provides for Sahelian-transition malaria science. The CFA franc argument is Sénégal’s most commercially decisive operational differentiator: every other sub-Saharan African country in the GCT series operates with a floating currency whose exchange rate volatility creates hedging costs, budget uncertainty, and financial planning complexity for multi-year Phase III programmes; Sénégal alone pegs to the Euro at a fixed irrevocable rate, giving EUR-denominated pharmaceutical sponsors; the majority of European companies, including France’s Sanofi, Servier, and Institut Mérieux, whose African research investment decisions are denominated in EUR; the same financial certainty in Dakar as in Lyon or Bordeaux. The Francophone gateway argument adds Sénégal’s most commercially strategic positioning: French-language DPLM regulatory submissions from Dakar are directly adaptable for the regulatory authorities of Côte d’Ivoire, Burkina Faso, Mali, Niger, Guinea, Benin, Togo, Cameroon, Gabon, and the Democratic Republic of Congo with a fraction of the translation and legal adaptation overhead required to port submissions from English-language African markets like Nigeria or Kenya; making Sénégal not just a national research market but the regulatory infrastructure investment that pays dividends across the 400-million-person Francophone African corridor for sponsors building genuinely pan-African research portfolios. Sénégal is where Africa’s yellow fever vaccine is made, where the continent’s oldest rural health surveillance has been running without interruption for over six decades, and where the only Euro-pegged currency in sub-Saharan Africa makes the financial planning of long-term research investment as predictable as anywhere in Europe.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.